2016 ACIP 美国成人免疫接种程序指南
Changes in the 2016 adult immunization schedule from the 2015 schedule included the following new ACIP recommendations:
•Interval change for 13-valent pneumococcal conjugate vaccine (PCV13) followed by 23-valent pneumococcal polysaccharide vaccine (PPSV23) from “6 to 12 months” to “at least 1 year” for adults aged ≥65 years who do not have immunocompromising conditions, anatomical or functional asplenia, cerebrospinal fluid leaks, or cochlear implants (1). The interval for adults aged ≥19 years with any of these conditions is at least 8 weeks (2).
•Serogroup B meningococcal (MenB) vaccine series should be administered to certain groups of persons aged ≥10 years who are at increased risk for serogroup B meningococcal disease (3).
•Men B vaccine series may be administered to adolescents and young adults aged 16 through 23 years (preferred age is 16 through 18 years) to provide short-term protection against most strains of serogroup B meningococcal disease (4).
•Nine-valent human papillomavirus (HPV) vaccine (9vHPV) has been added to the schedule and can be used for routine vaccination of females and males against HPV (5).
- 您可能感兴趣的指南
-